Compare Cipla with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs CADILA HEALTHCARE - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA CADILA HEALTHCARE CIPLA/
CADILA HEALTHCARE
 
P/E (TTM) x 29.6 24.9 118.9% View Chart
P/BV x 4.2 4.4 95.8% View Chart
Dividend Yield % 0.5 0.8 61.8%  

Financials

 CIPLA   CADILA HEALTHCARE
EQUITY SHARE DATA
    CIPLA
Mar-20
CADILA HEALTHCARE
Mar-20
CIPLA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs586352 166.2%   
Low Rs357207 172.8%   
Sales per share (Unadj.) Rs207.0139.2 148.7%  
Earnings per share (Unadj.) Rs18.611.8 158.1%  
Cash flow per share (Unadj.) Rs33.218.6 178.6%  
Dividends per share (Unadj.) Rs4.003.50 114.3%  
Dividend yield (eoy) %0.81.3 67.8%  
Book value per share (Unadj.) Rs195.5101.4 192.9%  
Shares outstanding (eoy) m806.351,023.74 78.8%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.32.0 113.4%   
Avg P/E ratio x25.323.7 106.7%  
P/CF ratio (eoy) x14.215.0 94.4%  
Price / Book Value ratio x2.42.8 87.4%  
Dividend payout %21.529.8 72.3%   
Avg Mkt Cap Rs m379,912286,033 132.8%   
No. of employees `00025.813.4 192.8%   
Total wages/salary Rs m30,27024,145 125.4%   
Avg. sales/employee Rs Th6,459.610,632.7 60.8%   
Avg. wages/employee Rs Th1,171.21,801.2 65.0%   
Avg. net profit/employee Rs Th580.2898.5 64.6%   
INCOME DATA
Net Sales Rs m166,949142,531 117.1%  
Other income Rs m3,4421,139 302.2%   
Total revenues Rs m170,391143,670 118.6%   
Gross profit Rs m32,06024,198 132.5%  
Depreciation Rs m11,7476,965 168.7%   
Interest Rs m1,9743,418 57.7%   
Profit before tax Rs m21,78214,954 145.7%   
Minority Interest Rs m-475288 -164.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,3123,198 197.4%   
Profit after tax Rs m14,99512,044 124.5%  
Gross profit margin %19.217.0 113.1%  
Effective tax rate %29.021.4 135.5%   
Net profit margin %9.08.5 106.3%  
BALANCE SHEET DATA
Current assets Rs m117,03887,154 134.3%   
Current liabilities Rs m43,93182,694 53.1%   
Net working cap to sales %43.83.1 1,399.4%  
Current ratio x2.71.1 252.8%  
Inventory Days Days9671 134.0%  
Debtors Days Days8594 90.7%  
Net fixed assets Rs m107,424133,236 80.6%   
Share capital Rs m1,6131,024 157.5%   
"Free" reserves Rs m156,018102,733 151.9%   
Net worth Rs m157,630103,757 151.9%   
Long term debt Rs m23,69332,146 73.7%   
Total assets Rs m236,626236,866 99.9%  
Interest coverage x12.05.4 223.9%   
Debt to equity ratio x0.20.3 48.5%  
Sales to assets ratio x0.70.6 117.3%   
Return on assets %7.26.5 109.9%  
Return on equity %9.511.6 82.0%  
Return on capital %12.813.7 93.5%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,03652,752 106.2%   
Fx outflow Rs m6,76414,504 46.6%   
Net fx Rs m49,27238,248 128.8%   
CASH FLOW
From Operations Rs m30,68525,054 122.5%  
From Investments Rs m1,040-10,123 -10.3%  
From Financial Activity Rs m-29,488-10,942 269.5%  
Net Cashflow Rs m2,3403,989 58.7%  

Share Holding

Indian Promoters % 16.0 74.8 21.4%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 8.3 147.0%  
FIIs % 23.7 5.9 401.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 11.0 238.2%  
Shareholders   161,166 44,069 365.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA  NOVARTIS  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Higher; JSW Steel & Tata Steel Top Gainers(09:30 am)

Asian share markets edged higher today as investors shrugged off concerns that stocks may have rallied too far too fast in the past year.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Mar 3, 2021 09:56 AM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS